Skip to Content

Home
About
Our Science
Programs & Pipeline
- Pipeline
- Clinical Trials
Patient Focus
- Patient Stories
- Disease Focus
Investors & Media

Careers
Contact

menu

Press Kit

Overview
Press Releases
Scientific Publications & Presentations
Corporate Presentation
Corporate Responsibility Report
Events & Presentations
Press Kit
Corporate Governance
Financial Info
Analyst Coverage
Investor Resources

Logo Downloads

Intellia Logo

Intellia Logo (reversed)
Photo Downloads

Intellia Therapeutics headquarters in Cambridge, Mass.
Infographic Downloads

Intellia Therapeutics: About Transthyretin (ATTR) Amyloidosis

Intellia Therapeutics: About Hereditary Angioedema (HAE)

Intellia Therapeutics: How NTLA-2001 Works

Intellia Therapeutics: How NTLA-2002 Works
Leadership Headshots

John Leonard, M.D.

President and
Chief Executive Officer

James Basta, J.D.

Executive Vice President,
General Counsel and Corporate Secretary

Eliana Clark, Ph.D.

Executive Vice President,
Chief Technical Officer

Edward Dulac

Executive Vice President,
Chief Financial Officer

David Lebwohl, M.D.

Executive Vice President,
Chief Medical Officer

Birgit Schultes, Ph.D.

Executive Vice President,
Chief Scientific Officer
CRISPR/Cas9 Resources

What is Genome Editing?

American Society of Gene and Cell Therapy

CRISPR/Cas9 – How it Works (Video)

Intellia Therapeutics

The Nobel Prize in Chemistry 2020

The Royal Swedish Academy of Sciences

CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers

National Institutes of Health, National Cancer Institute

Chief Medical Officer annual report 2016: generation genome

United Kingdom Department of Health & Social Care

Human Genome Editing: Science, Ethics, and Governance

The National Academies of Sciences, Engineering, Medicine

The Future of Therapeutic Genome Editing in European Healthcare Systems

Alliance for Regenerative Medicine

“CRISPR Guide,”

Addgene

What are genome editing and CRISPR-Cas9?

National Institutes of Health, Genetic Home Reference

Joint Statement of: Position Regarding Human Germline Gene Editing (Dec. 2015)

Intellia Therapeutics & CRISPR Therapeutics

Stay in the Know

Get Intellia’s press releases delivered to your inbox

Contacts

Press Releases Icon

Investor Relations

intelliatx@precisionaq.com

Press Releases Icon

Media Relations

media@intelliatx.com

Follow Us on

Social Media

Loading...

Cookie Policy
Terms of Use
Privacy Notice for HCPs
Privacy Policy

© 2025. Intellia Therapeutics, Inc.

Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.

You are leaving the
Intellia Therapeutics, Inc. website.

You may return to the Intellia Therapeutics, Inc. website by closing the window to the third-party website you have opened. Do you wish to continue?

When you are ready to return to the Intellia Therapeutics, Inc. website, simply close the window to the third-party website you have opened.

Yes No